A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
We are a New York City based clinical-stage biopharmaceutical company committed to advancing transformative therapies for the treatment of cancer and rare diseases. We were founded on the principle of applying modern scientific, regulatory or manufacturing advancements to established mechanisms in order to create new development opportunities. We prioritize creativity, diverse perspectives, integrity and tenacity to expedite our goal of bringing life-changing therapies to people with limited treatment options. Our portfolio includes two development programs utilizing TARA-002, an investigational cell therapy based on the broad immunopotentiator, OK-432, which was originally granted marketing approval by the Japanese Ministry of Health and Welfare as an immunopotentiating cancer therapeutic agent. TARA-002 is currently approved in Japan and Taiwan for lymphatic malformations, or LMs, and multiple oncologic indications.
| Metric | TTM | FY2020 | FY2014 |
|---|---|---|---|
| Revenue | 0 | - | - |
| Net Income | -53M | -34M | -9.7M |
| EPS | $-1.39 | $-4.70 | $-126.40 |
| Free Cash Flow | -49M | -24M | -10M |
| ROIC | -1569.0% | - | - |
| Gross Margin | - | - | - |
| Debt/Equity | 0.00 | - | - |
| Dividends/Share | $0.00 | - | - |
| Operating Income | -60M | -34M | -7.6M |
| Operating Margin | 0.0% | - | - |
| ROE | -40.0% | - | - |
| Shares Outstanding | 39M | 7M | 0M |
| Metric | |||
|---|---|---|---|
| Income Statement | |||
| Revenue | N/A | N/A | 0 |
| Gross Margin | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A |
| EBIT | -7.6M | -34M | -60M |
| Op. Margin | N/A | N/A | 0.0% |
| Net Income | -9.7M | -34M | -53M |
| Net Margin | N/A | N/A | 0.0% |
| Non-Recurring | 0 | 0 | 0 |
| Returns on Capital | |||
| ROIC | N/A | N/A | N/M |
| ROE | N/A | N/A | -40.0% |
| ROA | -21.4% | -33.2% | -1757.5% |
| Cash Flow | |||
| Op. Cash Flow | -10.0M | -23M | -49M |
| Free Cash Flow | -10M | -24M | -49M |
| Owner Earnings | -10M | -33M | -59M |
| CapEx | 51K | 884K | 0 |
| Maint. CapEx | 30K | 103K | 103K |
| Growth CapEx | 21K | 781K | 0 |
| D&A | 30K | 103K | 103K |
| CapEx/OCF | N/A | N/A | 0.0% |
| Capital Allocation | |||
| Dividends Paid | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | 0.0% |
| Stock-Based Comp | 459K | 9.7M | 9.7M |
| Debt Repayment | 0 | 1.7M | 1.7M |
| Balance Sheet | |||
| Net Debt | N/A | N/A | -133M |
| Cash & Equiv. | N/A | N/A | 133M |
| Long-Term Debt | N/A | N/A | N/A |
| Debt/Equity | N/A | N/A | 0.00 |
| Interest Coverage | -8.8 | -1013.1 | -1013.1 |
| Equity | N/A | N/A | 132M |
| Total Assets | 85M | 203M | 3.0M |
| Total Liabilities | N/A | N/A | 12M |
| Intangibles | N/A | 30M | 30M |
| Retained Earnings | -110M | -47M | -47M |
| Working Capital | 82M | 167M | 167M |
| Current Assets | 85M | 169M | 169M |
| Current Liabilities | 2.3M | 2.9M | 2.9M |
| Per Share Data | |||
| EPS | -126.40 | -4.70 | -1.39 |
| Owner EPS | -25.48 | -4.60 | -1.52 |
| Book Value | N/A | N/A | 3.43 |
| Cash Flow/Share | -24.29 | -3.24 | -1.37 |
| Dividends/Share | N/A | N/A | 0.00 |
| Shares Out. | 0.4M | 7.2M | 38.6M |
| Valuation | |||
| P/E Ratio | N/A | N/A | -3.7 |
| P/FCF | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A |
| Price/Book | N/A | N/A | 1.5 |
| Price/Sales | N/A | N/A | N/A |
| FCF Yield | -6.2% | -13.4% | -24.6% |
| Market Cap | 162M | 182M | 198M |
| Avg. Price | 402.77 | 26.12 | 5.13 |
| Year-End Price | 392.80 | 25.13 | 5.13 |
Protara Therapeutics, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Protara Therapeutics, Inc. (TARA) has a market capitalization of $198M. It is classified as a small-cap stock.
Protara Therapeutics, Inc. (TARA) does not currently pay a regular dividend.
Protara Therapeutics, Inc. (TARA) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Protara Therapeutics, Inc. (TARA) generated $-24 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Protara Therapeutics, Inc. (TARA) reported earnings per share (EPS) of $-4.70 in its most recent fiscal year.
The Ledger Terminal provides 2 years of financial data for Protara Therapeutics, Inc. (TARA), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.